Form 4: Director Roberto Mignone Exercises Guardant Health RSUs

Director Roberto Mignone acquired 264 shares of Guardant Health common stock through the vesting of restricted stock units.

Summary

• Director Roberto Mignone exercised 264 restricted stock units (RSUs) on April 21, 2026.
• The transaction resulted in the acquisition of 264 shares of common stock at a price of $0 per share.
• Following the transaction, the director holds 4,751 shares of common stock directly.
• The RSUs were part of an award granted on November 8, 2024, which vests over a four-year period.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative vesting of equity compensation rather than a discretionary market trade.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The remaining 75% of the November 8, 2024, RSU award continues to vest on a monthly basis over the three-year period following the initial vesting date.

Industry Context

StockSavvy.ai notes that routine RSU vesting for directors is a standard component of executive and board compensation packages in the biotechnology sector, signaling continued commitment rather than a change in strategic outlook.

Comparison to Industry Standards

• The transaction follows standard equity compensation practices for board members in the healthcare and diagnostics industry.
• The vesting schedule is consistent with typical four-year equity retention programs used by peers like Exact Sciences or Natera.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation-related transaction.

Next Steps

• Continued monthly vesting of the remaining RSU award balance.

Key Dates

Keywords

Guardant Health, GH, Form 4, Insider Trading, Equity Compensation, Roberto Mignone